Michael L. Cato

Michael L. Cato

Auto-generated profile, based on publicly available information

Michael L. Cato

Department of Biochemistry, Emory University School of Medicine, Atlanta, Georgia, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 March 2022 in Cell Chemical Biology
Verified
Journal Article
Closed access
SMSuzanne G. Mays
Suzanne G. Mays
EDEmma H. D’aGostino
Emma H. D’aGostino
AFAutumn R. Flynn
Autumn R. Flynn
XHXiangsheng Huang
Xiangsheng Huang
GWGuohui Wang
Guohui Wang
EOEric A. Ortlund
Eric A. Ortlund

3 May 2022 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
MCMichael L. Cato
Michael L. Cato
JCJeffery L. Cornelison
Jeffery L. Cornelison
RSRacheal M. Spurlin
Racheal M. Spurlin
VCValentine V. Courouble
Valentine V. Courouble
APAnamika B. Patel
Anamika B. Patel
EOEric A. Ortlund
Eric A. Ortlund

15 June 2023 in Journal of Biological Chemistry
Verified
Journal Article
Open access
MCMichael L. Cato
Michael L. Cato
EDEmma H. D’aGostino
Emma H. D’aGostino
RSRacheal M. Spurlin
Racheal M. Spurlin
AFAutumn R. Flynn
Autumn R. Flynn
JCJeffery L. Cornelison
Jeffery L. Cornelison
EOEric A. Ortlund
Eric A. Ortlund
Steroidogenic factor-1 (SF-1) is a phospholipid-sensing nuclear receptor expressed in the adrenal glands, gonads, and hypothalamus which controls steroidogenesis and metabolism. There is significant therapeutic interest in SF-1 because of its oncogenic properties in adrenocortical cancer. Synthetic modulators are attractive for targeting SF-1 for clinical and laboratory purposes due to the poor pharmaceutical properties of its native phospholipid ligands. While small molecule agonists targeting SF-1 have been synthesized, no crystal structures have been reported of SF-1 in complexes with synthetic compounds. This has prevented the establishment of structure-activity relationships that would enable better characterization of ligand-mediated activation and improvement in current chemical scaffolds. Here, we compare the effects of small molecules in SF-1 and its close homolog, liver receptor homolog-1 (LRH-1), and identify several molecules that specifically activate LRH-1. We also report the first crystal structure of SF-1 in complex with a synthetic agonist that displays low nanomolar affinity and potency for SF-1. We use this structure to explore the mechanistic basis for small molecule agonism of SF-1, especially compared to LRH-1, and uncover unique signaling pathways that drive LRH-1 specificity. Molecular dynamics simulations reveal differences in protein dynamics at the pocket mouth as well as ligand-mediated allosteric communication from this region to the coactivator binding interface. Our studies, therefore, shed important insight into the allostery driving SF-1 activity and show potential for modulation of LRH-1 over SF-1.

20 May 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
FFFilipp Frank
Filipp Frank
MKMeredith M. Keen
Meredith M. Keen
ARAnuradha Rao
Anuradha Rao
LBLeda Bassit
Leda Bassit
XLXu Liu
Xu Liu
EOEric A. Ortlund
Eric A. Ortlund
Widespread and frequent testing is critical to prevent the spread of COVID-19, and rapid antigen tests are the diagnostic tool of choice in many settings. With new viral variants continuously emerging and spreading rapidly, the effect of mutations on antigen test performance is a major concern. In response to the spread of variants the National Institutes of Health’s Rapid Acceleration of Diagnostics (RADx®) initiative created a Variant Task Force to assess the impact of emerging SARS-CoV-2 variants on in vitro diagnostic testing. To evaluate the impact of mutations on rapid antigen tests we developed a lentivirus-mediated mammalian surface-display platform for the SARS-CoV-2 Nucleocapsid protein, the target of the majority of rapid antigen tests. We employed deep mutational scanning (DMS) to directly measure the effect of all possible Nucleocapsid point mutations on antibody binding by 17 diagnostic antibodies used in 11 commercially available antigen tests with FDA emergency use authorization (EUA). The results provide a complete map of the antibodies’ epitopes and their susceptibility to mutational escape. This approach identifies linear epitopes, conformational epitopes, as well as allosteric escape mutations in any region of the Nucleocapsid protein. All 17 antibodies tested exhibit distinct escape mutation profiles, even among antibodies recognizing the same folded domain. Our data predict no vulnerabilities of rapid antigen tests for detection of mutations found in currently and previously dominant variants of concern and interest. We confirm this using the commercial tests and sequence-confirmed COVID-19 patient samples. The antibody escape mutation profiles generated here serve as a valuable resource for predicting the performance of rapid antigen tests against past, current, as well as any possible future variants of SARS-CoV-2, establishing the direct clinical and public health utility of our system. Further, our mammalian surface-display platform combined with DMS is a generalizable platform for complete mapping of protein-protein interactions.

4 November 2026 in Journal of Biological Chemistry
Verified
Journal Article
Open access
DBDebipreeta Bhowmik
Debipreeta Bhowmik
MCMichael L. Cato
Michael L. Cato
SASarah M. Abraham
Sarah M. Abraham
RSRacheal M. Spurlin
Racheal M. Spurlin
AFAutumn R. Flynn
Autumn R. Flynn
EOEric A. Ortlund
Eric A. Ortlund